Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

Research output: Contribution to journalReview articlepeer-review

184 Scopus citations


Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.

Original languageEnglish (US)
Pages (from-to)6549-6570
Number of pages22
JournalWorld Journal of Gastroenterology
Issue number36
StatePublished - Sep 28 2017


  • Alcoholic liver disease
  • Glucocorticoids
  • Liver transplantation
  • Non-alcoholic fatty liver disease
  • Treatment options

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Treatment options for alcoholic and non-alcoholic fatty liver disease: A review'. Together they form a unique fingerprint.

Cite this